IBO (impactbiomedinc.com) Return on Gross Profit

Impact BioMedical Inc (IBO) possesses moderate pricing power in the biosafety segment due to patents on plant-based compositions. The gross margin percentage reflects operational efficiency, with the current figure standing at -4026.30. The company is expanding its intellectual property system, planning strategic partnerships by 2026. Business growth is driven by the commercialization of the 3F repellent and the sale of technology licenses.
Financial and market metric breakdowns for Impact BioMedical, Inc. (IBO)

Conservative capital demands transparency in cost structures to assess business resilience to inflationary shocks. This indicator measures the profit margin after deducting direct production costs, determining the efficiency of cost management and the company's pricing power. For Impact BioMedical Inc (IBO), a high gross profit margin confirms low patent licensing costs and high profitability of royalties from biomedical developments.